When a patient experiences respiratory arrest—such as cardiac arrest, choking, or coma—if oxygen or effective ventilation cannot be promptly provided, prolonged brain hypoxia may result in irreversible damage. Particularly in scenarios without oxygen tanks, power sources, or in remote or disaster-stricken areas, traditional rescue methods face many limitations. Rescuers often lack equipment that provides isolation and positive-pressure ventilation. In such cases, a manual resuscitation bag can supply oxygen under pressure, maintaining patient life even without an oxygen source. This device is portable, easy to use, and requires no setup.

For patients with hypoxemia, dyspnea, or pneumonia, simple oxygen therapy alone may not effectively alleviate inflammatory responses or breathing difficulties. Combining aerosolized medication nebulization with oxygen humidification can promote pulmonary ventilation, improve secretion clearance, and relieve symptoms. This strategy is widely applied in chronic obstructive pulmonary disease (COPD), long-term oxygen therapy patients, postoperative care, acute and chronic respiratory infections, and post-COVID-19 rehabilitation stages. It achieves synergistic effects of oxygen supplementation combined with bronchodilators or saline nebulization, enhancing overall respiratory function and patient comfort.

Pulmonary rehabilitation has been internationally recognized by respiratory medical organizations as a core component in managing chronic respiratory diseases. Its purpose is to enhance respiratory muscle endurance, ventilation efficiency, and daily functional capacity, thereby reducing hospitalization risk and improving quality of life. Patients experiencing respiratory muscle imbalance, alveolar collapse, or mucus accumulation—such as postoperative patients, those with COPD, neurodegenerative diseases, or recovering from COVID-19—can achieve stabilized respiratory function through systematic training combined with assistive devices.

When a patient experiences respiratory arrest—such as cardiac arrest, choking, or unconsciousness—failure to provide immediate oxygen or effective ventilation can lead to prolonged brain hypoxia and irreversible damage. This risk is especially pronounced in situations lacking oxygen tanks, powered equipment, or in remote areas and disaster sites, where traditional rescue methods are often limited. First responders frequently lack access to devices that provide isolation and positive pressure ventilation capabilities.

Founded in 1986, GaleMed has been deeply engaged in the global respiratory care market under the GaleMed brand since 1996. It has now become a leading manufacturer of medical respiratory interface technologies. The company offers a comprehensive product line covering seven major areas: emergency rescue, respiratory therapy, anesthesia, oxygen therapy, aerosol therapy, sleep management, and more. Headquartered in Yilan, Taiwan, GaleMed provides over 5,000 SKUs marketed to more than 100 countries worldwide. Since 1995, the company has obtained multiple rigorous international certifications including ISO 9001, EN 46001, and CE. In 2024, GaleMed successfully achieved the European Union Medical Device Regulation (MDR) certification, demonstrating its professional expertise and commitment to sustainable operations.